Literature DB >> 32292559

Synthesis and Evaluation of Noncovalent Naphthalene-Based KEAP1-NRF2 Inhibitors.

Phillip R Lazzara1, Atul D Jain1, Amanda C Maldonado1, Benjamin Richardson1, Kornelia J Skowron1, Brian P David1, Zamia Siddiqui1, Kiira M Ratia1,2, Terry W Moore1,2,2.   

Abstract

The oxidative stress response, gated by the protein-protein interaction of KEAP1 and NRF2, has garnered significant interest in the past decade. Misregulation in this pathway has been implicated in disease states such as multiple sclerosis, rheumatoid arthritis, and diabetic chronic wounds. Many of the known activators of NRF2 are electrophilic in nature and may operate through several biological pathways rather than solely through the activation of the oxidative stress response. Recently, our lab has reported a nonelectrophilic, monoacidic, naphthalene-based NRF2 activator which exhibited good potency in vitro. Herein, we report a detailed structure-activity relationship of naphthalene-based NRF2 activators, an X-ray crystal structure of our monoacidic KEAP1 inhibitor, and identification of an underexplored area of the NRF2 binding pocket of KEAP1.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32292559      PMCID: PMC7153276          DOI: 10.1021/acsmedchemlett.9b00631

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

1.  The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase.

Authors:  Sara B Cullinan; John D Gordan; Jianping Jin; J Wade Harper; J Alan Diehl
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

2.  Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis.

Authors:  Zheng-Yu Jiang; Meng-Chen Lu; Li Li Xu; Ting-Ting Yang; Mei-Yang Xi; Xiao-Li Xu; Xiao-Ke Guo; Xiao-Jin Zhang; Qi-Dong You; Hao-Peng Sun
Journal:  J Med Chem       Date:  2014-02-21       Impact factor: 7.446

3.  Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.

Authors:  Meng-Chen Lu; Qiong Jiao; Tian Liu; Shi-Jie Tan; Hai-Shan Zhou; Qi-Dong You; Zheng-Yu Jiang
Journal:  Eur J Med Chem       Date:  2017-10-19       Impact factor: 6.514

4.  Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction.

Authors:  Daigo Inoyama; Yu Chen; Xinyi Huang; Lesa J Beamer; Ah-Ng Tony Kong; Longqin Hu
Journal:  J Biomol Screen       Date:  2011-12-07

Review 5.  NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease.

Authors:  A Boutten; D Goven; E Artaud-Macari; J Boczkowski; M Bonay
Journal:  Trends Mol Med       Date:  2011-04-01       Impact factor: 11.951

Review 6.  Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases.

Authors:  Antonio Cuadrado; Ana I Rojo; Geoffrey Wells; John D Hayes; Sharon P Cousin; William L Rumsey; Otis C Attucks; Stephen Franklin; Anna-Liisa Levonen; Thomas W Kensler; Albena T Dinkova-Kostova
Journal:  Nat Rev Drug Discov       Date:  2019-04       Impact factor: 84.694

Review 7.  Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents.

Authors:  Sadagopan Magesh; Yu Chen; Longqin Hu
Journal:  Med Res Rev       Date:  2012-05-01       Impact factor: 12.944

8.  Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol.

Authors:  Daniel Martin; Ana I Rojo; Marta Salinas; Raquel Diaz; German Gallardo; Jawed Alam; Carlos M Ruiz De Galarreta; Antonio Cuadrado
Journal:  J Biol Chem       Date:  2003-12-19       Impact factor: 5.157

9.  Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2.

Authors:  Akira Kobayashi; Moon-Il Kang; Hiromi Okawa; Makiko Ohtsuji; Yukari Zenke; Tomoki Chiba; Kazuhiko Igarashi; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

10.  An Essential Role of NRF2 in Diabetic Wound Healing.

Authors:  Min Long; Montserrat Rojo de la Vega; Qing Wen; Manish Bharara; Tao Jiang; Rui Zhang; Shiwen Zhou; Pak K Wong; Georg T Wondrak; Hongting Zheng; Donna D Zhang
Journal:  Diabetes       Date:  2015-12-30       Impact factor: 9.461

View more
  4 in total

1.  Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding Mode.

Authors:  Nikolaos Georgakopoulos; Sandeep Talapatra; Dina Dikovskaya; Sharadha Dayalan Naidu; Maureen Higgins; Jemma Gatliff; Aysel Ayhan; Roxani Nikoloudaki; Marjolein Schaap; Klara Valko; Farideh Javid; Albena T Dinkova-Kostova; Frank Kozielski; Geoffrey Wells
Journal:  J Med Chem       Date:  2022-05-12       Impact factor: 8.039

2.  Toxicological Screening of 4-Phenyl-3,4-dihydrobenzo[h]quinolin-2(1H)-one: A New Potential Candidate for Alzheimer's Treatment.

Authors:  Fareeha Anwar; Uzma Saleem; Atta Ur Rehman; Bashir Ahmad; Tariq Ismail; Muhammad Usman Mirza; Lee Yean Kee; Iskandar Abdullah; Sarfraz Ahmad
Journal:  ACS Omega       Date:  2021-04-16

3.  Identification of a potent Nrf2 displacement activator among aspirin-containing prodrugs.

Authors:  Irina N Gaisina; Dmitry M Hushpulian; Arsen M Gaisin; Eliot H Kazakov; Navneet Ammal Kaidery; Manuj Ahuja; Andrey A Poloznikov; Irina G Gazaryan; Gregory R J Thatcher; Bobby Thomas
Journal:  Neurochem Int       Date:  2021-07-27       Impact factor: 4.297

4.  A bioactive ligand-conjugated iridium(III) metal-based complex as a Keap1-Nrf2 protein-protein interaction inhibitor against acetaminophen-induced acute liver injury.

Authors:  Guodong Li; Hao Liu; Ruibing Feng; Tian-Shu Kang; Wanhe Wang; Chung-Nga Ko; Chun-Yuen Wong; Min Ye; Dik-Lung Ma; Jian-Bo Wan; Chung-Hang Leung
Journal:  Redox Biol       Date:  2021-09-10       Impact factor: 11.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.